Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
NCT07006532Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Randomised, open-label trial of tocilizumab in kidney transplant rejection (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Glomerular Filtration Rate at 1 year. Started Jan 2025; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT07006532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006532.